Pine Biotech has recently announced that it has secured $1,025,000 in seed funding from investors this May in support of the development and commercialization of their proprietary biomedical data analysis and machine-learning platform. Incorporated at the end of 2014, Pine Biotech is commercializing a biomedical data analysis platform in collaboration with the Tauber Bioinformatics Research Center and the University of Haifa.
The platform is designed to serve unmet needs in clinical studies, academic research, and education, enabling researchers to conduct comprehensive analysis of large genomic, transcriptomic, proteomic, structural, and phenotypic data using an intuitive interface. Molecular data reveals important mechanisms of action that are best studied as a system, making this integrative approach critical for understanding and treating disease.
The machine learning platform utilizes algorithms developed over years of research and training in many academic projects. In addition to making multi-omics analysis accessible for non-bioinformaticians, the platform includes a machine-learning toolkit and interactive visualization. “Our company’s focus is on analysis of molecular data, or "omics" data, because it contains information on an unprecedented level of precision,” says CEO Elia Brodsky, “By enabling researchers and clinicians to extract real insight from omics data, we hope that new and more effective approaches to diagnostics and therapeutics will be developed.” The funding comes in support of newly secured collaborations with government agencies, academic medical centers, and technology partners. “Now our team will be able to move our work out of the research space, and start addressing clinical challenges together with our partners.” To learn more about Pine Biotech, visit the website www.pine-biotech.com.